Description
FTC-133 was obtained from a lymph node metastasis of a follicular thyroid carcinoma not the primary tumour as originally reported (Rao AS, Goretzki PE, Köhrle J, Brabant G 2005 Letter Re Id1 gene expression in hyperplastic and neoplastic thyroid tissues. J Clin Endocrinol Metab. 90(10)5906 PMID 16207897) from a 42-year-old male. The morphology differs from flat polygonal to spindle formed cells. They retained differentiated thyrocyte function and thyrocyte responsiveness to thyrotropin and local active growth factors. Thyroglobulin immunoreactivity could be shown in the cytoplasm and EGF receptor immunoreactivity could be visualised on the cell membranes. Complex chromosomal changes were detected as well as a p53 mutation. FTC-133 (ECACC Catalogue number 94060901), FTC-236 (ECACC Catalogue number 06030202) and FTC-238 (ECACC Catalogue number 94060902) were all derived from the same individual, a 42 year old male with follicular thyroid cancer. This has been confirmed by short tandem repeat STR-PCR analysis at ECACC The Y chromosome could not be detected in these cell line by (STR)-PCR analysis. It is a known phenomenon that due to the increased genetic instability of cancer cell lines the Y chromosome can be rearranged or lost resulting in lack of detection. The cell lines are identical to the source provided by the depositor based on the STR-PCR analysis.
Adherent Suspension
Adherent
Suggested Medium
DMEMHam's F12 (11) + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).
Quality Control
Cell lines were tested and found to be free of mycoplasma, bacterial, viruses, and other toxins. All cells were above 95% viability before freezing.
Tissue
Thyroid (lymph node metastasis)
Shippment
The cells are shipped using dry ice.
Storage
Store the cell lines in liquid nitrogen vapor (less than -130°C)
Warranty
Our cell products are for research use only. They are not authorized for human, in vitro diagnostic procedures or for therapeutic procedures.
